Towa Aims To Restore Japanese Trust In Generics Quality
‘Future Of Generics Companies Are Worrisome’
Japan’s Towa Pharmaceutical has published its fifth mid-term business plan, alongside financial results for the 12 months ended 31 March 2021.
You may also be interested in...
Japan’s Sawai has laid out its mid- and long-term ambitions in a new company business plan, spanning both its local and overseas operations.
A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.
CDMO Catalent and US health insurance giant Anthem have joined up with non-profit Civica’s new outpatient-focused generics business arm, CivicaScript, with plans to begin rolling out products as early as next year.